Haemonetics Corporation (NYSE:HAE) - Investment analysts at Barrington Research raised their Q3 2018 earnings per share (EPS) estimates for shares of Haemonetics Corporation in a research note issued to investors on Tuesday. Barrington Research analyst M. Petusky now expects that the medical instruments supplier will post earnings per share of $0.45 for the quarter, up from their prior estimate of $0.43. Barrington Research currently has a “Outperform” rating and a $48.00 price target on the stock. Barrington Research also issued estimates for Haemonetics Corporation’s Q4 2018 earnings at $0.41 EPS, FY2018 earnings at $1.65 EPS and FY2019 earnings at $1.85 EPS.
A number of other research analysts have also recently issued reports on the stock. Zacks Investment Research raised shares of Haemonetics Corporation from a “hold” rating to a “buy” rating and set a $47.00 price objective on the stock in a research note on Wednesday. TheStreet upgraded shares of Haemonetics Corporation from a “c” rating to a “b-” rating in a research report on Monday. BidaskClub upgraded shares of Haemonetics Corporation from a “strong sell” rating to a “sell” rating in a report on Tuesday. Jefferies Group LLC reiterated a “buy” rating and set a $48.00 price target on shares of Haemonetics Corporation in a report on Thursday, July 27th. Finally, JMP Securities upgraded shares of Haemonetics Corporation from a “market perform” rating to an “outperform” rating and set a $50.00 price target on the stock in a report on Thursday, July 13th. Two analysts have rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $40.63.
Shares of Haemonetics Corporation (HAE) traded down 1.69% during trading on Thursday, reaching $41.80. The company had a trading volume of 146,300 shares. Haemonetics Corporation has a 12 month low of $32.76 and a 12 month high of $43.74. The company has a market cap of $2.20 billion, a price-to-earnings ratio of 542.86 and a beta of 0.90. The firm has a 50 day moving average price of $40.10 and a 200 day moving average price of $40.13.
Haemonetics Corporation (NYSE:HAE) last issued its quarterly earnings results on Monday, August 7th. The medical instruments supplier reported $0.33 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.31 by $0.02. Haemonetics Corporation had a return on equity of 11.07% and a net margin of 0.48%. The firm had revenue of $211 million for the quarter, compared to analyst estimates of $211.29 million. During the same period in the previous year, the company posted $0.25 earnings per share. The company’s quarterly revenue was up .5% compared to the same quarter last year.
In related news, Director Ronald Merriman sold 17,471 shares of the company’s stock in a transaction that occurred on Monday, May 22nd. The shares were sold at an average price of $40.33, for a total transaction of $704,605.43. Following the sale, the director now owns 24,925 shares of the company’s stock, valued at approximately $1,005,225.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 1.20% of the company’s stock.
Several institutional investors have recently modified their holdings of the company. BlackRock Inc. boosted its stake in shares of Haemonetics Corporation by 48,854.9% in the first quarter. BlackRock Inc. now owns 6,289,728 shares of the medical instruments supplier’s stock worth $255,175,000 after buying an additional 6,276,880 shares during the period. Vanguard Group Inc. boosted its stake in shares of Haemonetics Corporation by 7.6% in the first quarter. Vanguard Group Inc. now owns 4,694,325 shares of the medical instruments supplier’s stock valued at $190,449,000 after buying an additional 332,087 shares during the last quarter. Wellington Management Group LLP boosted its stake in shares of Haemonetics Corporation by 22.6% in the first quarter. Wellington Management Group LLP now owns 4,192,350 shares of the medical instruments supplier’s stock valued at $170,084,000 after buying an additional 774,089 shares during the last quarter. Wells Fargo & Company MN boosted its stake in shares of Haemonetics Corporation by 9.3% in the second quarter. Wells Fargo & Company MN now owns 2,788,122 shares of the medical instruments supplier’s stock valued at $110,104,000 after buying an additional 238,294 shares during the last quarter. Finally, Victory Capital Management Inc. boosted its stake in shares of Haemonetics Corporation by 11.0% in the first quarter. Victory Capital Management Inc. now owns 2,394,135 shares of the medical instruments supplier’s stock valued at $97,130,000 after buying an additional 236,481 shares during the last quarter.
About Haemonetics Corporation
Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.
Receive News & Ratings for Haemonetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.
